Trial Profile
A Phase II Trial of Prostaglandin E2 Inhibition, Using Meloxicam, Plus Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary) ; Meloxicam (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 02 Feb 2021 Status changed from active, no longer recruiting to completed.
- 17 Dec 2020 Planned End Date changed from 1 Jan 2020 to 1 Jan 2021.
- 17 Dec 2020 Status changed from recruiting to active, no longer recruiting.